{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T09:43:14Z","timestamp":1793871794432,"version":"4.6.1"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"19","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Kowa Research Institute"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["3165-00227B"],"award-info":[{"award-number":["3165-00227B"]}],"id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Guidelines focus on individuals with triglycerides between 2.3 and 5.6\u2005mmol\/L (200 and 499\u2005mg\/dL). The hypotheses that triglycerides across the full biological range and within this constrained range associated with cardiovascular risk were re-assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Multivariable-adjusted hazard ratios for major cardiovascular events and death according to baseline triglycerides among 119 573 individuals with triglycerides across the full biological range from the Copenhagen General Population Study, among 27 757 individuals with baseline triglycerides between 2.3 and 5.6 mmol\/L from the Copenhagen General Population Study and the Women\u2019s Health Study cohorts, and among 31 272 individuals with mild-to-moderate hypertriglyceridaemia from the PROMINENT, REDUCE-IT, and STRENGTH trials were calculated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Increasing triglycerides across the full range (0.3 to 11.2 mmol\/L) were associated with an increasing risk of major cardiovascular events (N = 12 241). In the cohorts, combined hazard ratios [95% confidence interval (triglyceride range in mmol\/L)] for major cardiovascular events (N = 3928) from lowest to highest triglyceride quartile were 1.0 [referent (range: &amp;lt; 2.5)], 0.95 [0.87\u20131.04 (range: 2.5 to &amp;lt;3.0)], 1.04 [0.95\u20131.13 (range: 3.0 to &amp;lt;3.6)], and 1.13 [1.04\u20131.23 (range: \u2265 3.6)]. In the three contemporary trials, the corresponding hazard ratios (N = 4265 cardiovascular events) from lowest to highest quartile were 1.0 [referent (ranges for PROMINENT\/REDUCE-IT\/STRENGTH: &amp;lt; 2.6\/2.0\/2.2)], 1.01 [0.93\u20131.10 (ranges: 2.6 to &amp;lt;3.1\/2.0 to &amp;lt;2.5\/2.2 to &amp;lt;2.7)], 1.05 [0.96\u20131.14 (ranges: 3.1 to &amp;lt;3.9\/2.5 to &amp;lt;3.1\/2.7 to &amp;lt; 3.5)] and 1.09 [1.00\u20131.19 (ranges: \u2265 3.9\/3.1\/3.5)]. In neither cohorts nor trials were triglycerides across this range strongly associated with risk of cardiovascular or all-cause death.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Individuals with mild-to-moderate hypertriglyceridaemia may not express the same magnitude of cardiovascular risk as that observed across the full range of plasma triglycerides. Future triglyceride-lowering therapy trials may want to consider enrolment across a wider range of triglyceride levels if there is no prior history of pancreatitis nor excessive alcohol intake.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaf074","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T20:17:47Z","timestamp":1738181867000},"page":"1835-1848","source":"Crossref","is-referenced-by-count":21,"title":["Expanding the triglyceride range in clinical trials: therapeutic opportunities"],"prefix":"10.1093","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5500-686X","authenticated-orcid":false,"given":"Ask T","family":"Nordestgaard","sequence":"first","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]},{"name":"Department of Clinical Biochemistry and the Copenhagen General Population Study, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna D","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M","family":"Everett","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean G","family":"MacFadyen","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai , New York, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L J","family":"Visseren","sequence":"additional","affiliation":[{"name":"Department of Vascular Medicine, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-502X","authenticated-orcid":false,"given":"Peter","family":"Libby","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D","family":"Santos","sequence":"additional","affiliation":[{"name":"Academic Research Organization, Hospital Israelita Albert Einstein & Lipid Clinic Heart Institute (InCor), University of S\u00e3o Paulo Medical School Hospital , S\u00e3o Paulo SP ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E","family":"Nissen","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic , Cleveland, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00f8rge G","family":"Nordestgaard","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry and the Copenhagen General Population Study, Copenhagen University Hospital\u2014Herlev and Gentofte , Herlev ,","place":["Denmark"]},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-4522","authenticated-orcid":false,"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]},{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"2025052711430941800_ehaf074-B1","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"2025052711430941800_ehaf074-B2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1161\/01.CIR.60.3.473","article-title":"Atherogenesis: a postprandial phenomenon","volume":"60","author":"Zilversmit","year":"1979","journal-title":"Circulation"},{"key":"2025052711430941800_ehaf074-B3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1161\/01.ATV.11.3.569","article-title":"Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans","volume":"11","author":"Shaikh","year":"1991","journal-title":"Arterioscler Thromb"},{"key":"2025052711430941800_ehaf074-B4","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2025052711430941800_ehaf074-B5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025052711430941800_ehaf074-B6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B8","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1093\/eurheartj\/ehad337","article-title":"Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study","volume":"44","author":"Bj\u00f6rnson","year":"2023","journal-title":"Eur Heart J"},{"key":"2025052711430941800_ehaf074-B9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jama.298.3.309","article-title":"Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women","volume":"298","author":"Bansal","year":"2007","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jama.298.3.299","article-title":"Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women","volume":"298","author":"Nordestgaard","year":"2007","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B11","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 fatty acid supplements in diabetes Mellitus","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B14","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B15","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1001\/jama.299.21.2524","article-title":"Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease","volume":"299","author":"Frikke-Schmidt","year":"2008","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1373\/clinchem.2007.099366","article-title":"Rationale, design, and methodology of the women\u2019s genome health study: a genome-wide association study of more than 25 000 initially healthy American women","volume":"54","author":"Ridker","year":"2008","journal-title":"Clin Chem"},{"key":"2025052711430941800_ehaf074-B17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa050613","article-title":"A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1002\/clc.22692","article-title":"Rationale and design of REDUCE-IT: reduction of cardiovascular events with icosapent ethyl-intervention trial","volume":"40","author":"Bhatt","year":"2017","journal-title":"Clin Cardiol"},{"key":"2025052711430941800_ehaf074-B19","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"key":"2025052711430941800_ehaf074-B20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the pemafibrate to reduce cardiovascular outcomes by reducing triglycerides in patients with diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"2025052711430941800_ehaf074-B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1089\/152460900318911","article-title":"Baseline characteristics of participants in the women\u2019s health study","volume":"9","author":"Rexrode","year":"2000","journal-title":"J Womens Health Gend Based Med"},{"key":"2025052711430941800_ehaf074-B22","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1001\/jama.2016.4666","article-title":"Change in body mass index associated with lowest mortality in Denmark, 1976\u20132013","volume":"315","author":"Afzal","year":"2016","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B23","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3462-1","volume-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis","author":"Harell","year":"2001"},{"key":"2025052711430941800_ehaf074-B24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C\u2013lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B25","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B27","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events. VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"2025052711430941800_ehaf074-B28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki heart study: implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"2025052711430941800_ehaf074-B29","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2025052711430941800_ehaf074-B30","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2025052711430941800_ehaf074-B31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease","volume":"102","author":"Behar","year":"2000","journal-title":"Circulation"},{"key":"2025052711430941800_ehaf074-B32","doi-asserted-by":"publisher","first-page":"CD003177","DOI":"10.1002\/14651858.CD003177.pub5","article-title":"Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease","volume":"3","author":"Abdelhamid","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052711430941800_ehaf074-B33","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.jacc.2019.06.043","article-title":"Reduction in first and total ischemic events with icosapent ethyl across baseline triglyceride tertiles","volume":"74","author":"Bhatt","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025052711430941800_ehaf074-B34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.pharmthera.2010.01.008","article-title":"Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk","volume":"126","author":"Chapman","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2025052711430941800_ehaf074-B35","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","article-title":"Clinical trial design for triglyceride-rich lipoprotein-lowering therapies: JACC focus seminar 3\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025052711430941800_ehaf074-B36","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1093\/eurheartj\/ehab555","article-title":"A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs","volume":"42","author":"Doi","year":"2021","journal-title":"Eur Heart J"},{"key":"2025052711430941800_ehaf074-B37","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCULATIONAHA.122.059410","article-title":"Effects of randomized treatment with icosapent ethyl and a mineral oil comparator on interleukin-1\u00df, interleukin-6, C-reactive protein, oxidized low-density lipoprotein cholesterol, homocysteine, lipoprotein(a), and lipoprotein-associated phospholipase A2: a REDUCE-IT biomarker substudy","volume":"146","author":"Ridker","year":"2022","journal-title":"Circulation"},{"key":"2025052711430941800_ehaf074-B38","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"2025052711430941800_ehaf074-B39","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025052711430941800_ehaf074-B40","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025052711430941800_ehaf074-B41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12944-021-01449-1","article-title":"The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids Health Dis"},{"key":"2025052711430941800_ehaf074-B42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jacc.2008.03.051","article-title":"Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials","volume":"52","author":"Nicholls","year":"2008","journal-title":"J Am Coll Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/19\/1835\/61898261\/ehaf074.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/46\/19\/1835\/61898261\/ehaf074.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:43:14Z","timestamp":1748360594000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/46\/19\/1835\/8015506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":42,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2025,2,14]]},"published-print":{"date-parts":[[2025,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaf074","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5,14]]},"published":{"date-parts":[[2025,2,14]]}}}